Q4 2025 + FY2025 Wrap: Strong Close, 2026 Procedure Guide Moderates to 13-15% — Maintaining Outperform
Key Takeaways
- Q4 revenue $2.87B (+19% YoY) and pro forma EPS $2.53 (+14%) beat Street modestly. FY25 closes at $10.1B revenue (+21%) and pro forma EPS +22% — 3rd consecutive year of 20%+ EPS growth. Free cash flow $2.5B (vs $1.3B FY24, +92%). 3.1M+ procedures performed in 2025; 1,721 da Vinci system placements (incl. 870 dV5). Capital returned $2.3B in FY25 at avg $478/share.
- 2026 initial procedure guide of 13-15% vs FY25 actual 18% represents notable deceleration. Conservative initial guide consistent with ISRG pattern, but the magnitude of the moderation tempered the print's enthusiasm. Pro forma GM guide 67-68% (incl. 120bp tariff impact). FY25 pre-announced metrics at JPM Healthcare on Jan 14 limited the surprise factor of the Jan 22 print.
- Strategic milestones: cardiac dV5 FDA clearance (new TAM); SP NSM + inguinal hernia + cholecystectomy + appendectomy clearances expand TAM materially; Italy/Spain/Portugal direct conversion closing Q1 2026 (~250 employee transfer); ASC strategy progressing via XiR-based offerings (70% of opportunity in IDN-affiliated ASCs). 18 of 20 largest IDNs have dV5; 21 fully standardized.
- Q4 gross margin 67.8% (-170bp YoY) compressed on 95bp tariff impact + $70M Intuitive Foundation donation (multi-year, pulled forward due to 2026 tax rules) + product mix. Q4 operating margin 37% — below FY25 average of 37% but in line with expected Q4 trajectory. Pro forma EPS $2.53 with the $70M donation (~$0.15 EPS impact) reducing comparability.
- Rating: Maintaining Outperform. Stock +0.5% to ~$558 reflects the deceleration concern offsetting the operational beats. FY25 wrap is strong; 2026 guide is conservative consistent with multi-year ISRG pattern. PT range maintained Base $640 / Bull $720 / Bear $500. The Q1 print will be the next test of whether 2026 starts at the top of guide range.
Results vs. Consensus
The Q4 print was effectively the second leg of a two-part disclosure: preliminary metrics were pre-announced at JPM Healthcare on Jan 14, with the Jan 22 print providing margin + EPS detail + 2026 guidance. The pre-announcement compressed the surprise factor; the headline news was the 2026 procedure growth guide of 13-15% — a meaningful step-down from FY25 actual 18%.
| Metric | Q4 Actual | Consensus | Beat/Miss | Magnitude |
|---|---|---|---|---|
| Revenue | $2.87B (+19%) | $2.85B | Beat | +$20M (pre-announced) |
| da Vinci Procedures | +17% | +17% (pre-announced) | In-line | n/a |
| System Placements | 532 (+8%) | 532 (pre-announced) | In-line | n/a |
| Pro Forma Gross Margin | 67.8% | ~67.5% | Beat | +30bp |
| Pro Forma Op Margin | 37% | ~37% | In-line | n/a |
| Pro Forma EPS | $2.53 (+14%) | $2.42 | Beat | +$0.11 |
| GAAP EPS | $2.21 | ~$2.08 | Beat | +$0.13 |
FY2025 vs Original Guide
| Metric | FY25 Actual | FY25 Original Guide | FY25 Final Guide (Q3) |
|---|---|---|---|
| Revenue | $10.1B (+21%) | ~$9.8B (implied) | $10.0B (implied) |
| da Vinci Procedure Growth | 18% | 15-17% | 17-17.5% |
| Pro Forma Gross Margin | 67.6% | 65-66.5% | 67-67.5% |
| Free Cash Flow | $2.5B | ~$2.0B | n/a |
| EPS Growth | +22% | n/a | n/a |
YoY View
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Revenue | $2.87B | $2.41B | +19% |
| da Vinci Procedures | +17% | +18% | Modest decel |
| System Placements | 532 | 493 | +8% |
| Pro Forma EPS | $2.53 | $2.21 | +14% |
| Pro Forma Gross Margin | 67.8% | 69.5% | -170bp |
Revenue Assessment
Q4 revenue +19% YoY with broad-based contributions: da Vinci procedures +17%; Ion +44%; SP +78%. US +16% (vs OUS +22% day-adjusted) reflects continued OUS multi-specialty acceleration. After-hours procedures +35% YoY in US — proxy for acute care + capacity expansion at customer hospitals. System placements 532 (+8%) with 303 dV5 (43 OUS); installed base 1,232 dV5. Trade-ins 146 (vs 62 YoY) — sustained dV5 upgrade momentum. ASP increase to $1.68M from $1.6M on dV5 mix + dual-console mix.
Margin Assessment
Pro forma GM 67.8% (-170bp YoY) — Q4 impact split between 95bp tariff (largest of FY25 as tariff expense flows through inventory) + higher facility costs + dV5/Ion mix. Operating margin 37% — typical seasonal Q4 step-down + $70M Intuitive Foundation donation. FY25 full-year operating margin 37% (+70bp YoY) — discipline intact through tariff + platform-transition headwinds. The $70M donation was a deliberate decision to pull forward multi-year giving before 2026 tax rule changes.
EPS Assessment
Pro forma EPS $2.53 (+14%) — operationally lower growth rate vs Q3 reflects (a) $70M Intuitive Foundation donation, (b) 95bp Q4 tariff impact, (c) lower tax rate benefit vs Q3 (20.6% vs 18.3%). Excluding the donation, EPS would have grown ~+20%. Q4 buyback modest at $201M (smaller pace vs Q3's $1.9B). FY25 EPS growth +22% — third consecutive 20%+ year. The trajectory is durable.
Segment Performance
da Vinci — Q4 +17% / FY25 +18% / dV5 Mix-Up
Q4 da Vinci procedures +17%; FY25 +18% — best procedure growth in 5+ years. Q4 system placements 532 (303 dV5; installed base 1,232 dV5). FY25 1,721 total placements (870 dV5; 107 SP; 42 XiR). dV5 mix-up driving accretive ASP. In US, 18 of 20 largest IDNs have dV5; 21 fully standardized. Trade-ins 146 Q4 / 388 FY25 demonstrating sustained Xi→dV5 upgrade cycle.
Assessment: da Vinci durably compounding. Multi-year dV5 transition has ~3-5 years of upgrade runway given ~10K Xi systems globally.
Ion — Q4 +44% / FY25 +51% (144K procedures total)
Q4 Ion procedures +44%; FY25 144K+ procedures (+51%). System placements 42 Q4 (vs 69) / 195 FY25. Installed base approaching 1,000 systems. Australia + Korea first commercial sales completed.
Assessment: Ion economics compounding through utilization. Multi-year lung cancer market opportunity remains structural.
SP — Q4 +78% / FY25 +87% / Multiple US Clearances
SP Q4 procedures +78%; FY25 +87%. NSM + inguinal hernia + cholecystectomy + appendectomy US clearances received in Q4. Installed base 377 systems (+39% YoY).
Assessment: SP TAM expansion is the H2 2026 inflection. NSM measured launch 2026.
Key Topics & Management Commentary
Overall Management Tone: Confident on FY25 wrap; measured on 2026 outlook. The 13-15% procedure growth guide reflects conservative posture + acknowledged macro headwinds (ACA/Medicaid policy uncertainty + Japan/China continued pressure + bariatrics decline + capital constraints).
1. FY25 Wrap — 21% Revenue, 22% EPS, $2.5B FCF
FY25 closes as the strongest growth year in 5+ years. Revenue +21%, EPS +22%, FCF $2.5B (+92% YoY).
"2025 was a strong year for Intuitive, driven by multispecialty da Vinci procedure growth across the globe, increasing adoption of da Vinci 5 and higher utilization across our 3 platforms. Physicians used our systems to treat more than 3.1 million patients in the year." — David Rosa, CEO
Assessment: Best year in recent memory. Multi-quarter compounder thesis validated.
2. 2026 Procedure Growth Guide 13-15%
Conservative initial 2026 guide of 13-15% vs FY25 18%. Factors cited: ACA/Medicaid policy uncertainty, Japan/China continued pressure, bariatrics decline, capital constraints.
Assessment: ISRG historically issues conservative initial guides. Actual likely lands at top of range or above (FY25 finished 17-17.5% raised guide → 18% actual).
3. Cardiac dV5 FDA Clearance
Cardiac procedures FDA cleared on dV5 (non-FF instruments). Measured rollout planned.
Assessment: Cardiac is a meaningful new TAM. Multi-year ramp; revenue contribution 2027+.
4. SP US TAM Expansion (NSM + Gen Surg)
NSM + inguinal hernia + cholecystectomy + appendectomy SP clearances received Q4. Multi-year US TAM expansion.
Assessment: SP US revenue ramp accelerating in 2026-2027. Multi-billion dollar opportunity at scale.
5. ASC Strategy Progressing
ASC strategy leveraging XiR + economic offerings. 70% of ASC opportunity in IDN-affiliated ASCs. Multi-year effort.
Assessment: ASC channel is incremental TAM. Long ramp; meaningful contribution by FY27-FY28.
6. Italy/Spain/Portugal Direct Conversion
Distributor acquisition closing Q1 2026 with ~250 employee transfer. Going-direct strategy continuation.
Assessment: Initial OpEx drag in Q1-Q2 2026; margin benefit emerges 2026 H2 + 2027.
7. $70M Intuitive Foundation Donation
$70M donation pulled forward as multi-year commitment due to 2026 tax rule changes. ~$0.15 Q4 EPS impact.
Assessment: One-time accelerated giving. Adjusted comparability for Q1 2026.
8. Tariff Impact 95bp Q4 (Largest of FY25)
Q4 tariff impact 95bp — largest of FY25. FY26 forecast 120bp +/- 10bp.
Assessment: Tariff headwind in FY26; modest but structural. Bulgaria + Mexico manufacturing footprint provides flexibility.
9. ACA/Medicaid Policy Uncertainty
ACA premium subsidy expiration + Medicaid funding changes flagged as 2026 risk. ISRG has lower Medicaid penetration; framework for resilience.
Assessment: Policy uncertainty is the largest 2026 macro risk. Q1 2026 will provide early visibility on impact.
10. Free Cash Flow $2.5B (+92% YoY)
FCF $2.5B vs $1.3B FY24 — driven by profitability + lower capex. CapEx guidance no longer provided as returning to normalized levels.
Assessment: FCF inflection meaningful. Supports continued accelerated capital return at depressed prices.
Guidance & Outlook
| Metric | 2026 Initial Guide | FY25 Actual | Comparison |
|---|---|---|---|
| da Vinci Procedure Growth | 13-15% | 18% | Deceleration |
| Pro Forma Gross Margin | 67-68% | 67.6% | Roughly flat |
| Tariff Impact | 120bp +/- 10bp | ~70bp | Headwind |
| Pro Forma OpEx Growth | 11-15% | 12% | In-line |
| Pro Forma Tax Rate | 22-23% | 21% | Modest headwind |
Analyst Q&A Highlights
2026 Procedure Growth Deceleration Conservative or Honest?
Q: "13-15% 2026 procedure growth implies 300-500bp deceleration. Is this conservative consistent with prior pattern, or honest reflection of headwinds?"
— Larry Biegelsen, Wells Fargo
A: "Our updated range continues to consider the potential impact of changes to ACA premium subsidies and patient behavior in the U.S., capital pressure in parts of Europe related to macroeconomic impact and shifting governmental priorities, China's tender volumes and competitive intensity in that market, recent capital challenges in Japan and how long those persist in 2026, and pharmaceutical products for obesity management."
— Daniel Connally, Head of Investor Relations
Assessment: Headwinds enumerated. Consistent with ISRG's conservative-guide pattern. FY26 likely lands 15-16% if pattern holds.
Cardiac dV5 Opportunity Sizing
Q: "Cardiac clearance is a major new TAM. How big is the opportunity and what's the ramp?"
— Robbie Marcus, JPMorgan
A: "Given the complexity of minimally invasive cardiac surgery, we are planning a measured rollout to support training, education and adoption. We believe deeply that patients requiring cardiac surgery can benefit from a minimally invasive approach with da Vinci."
— David Rosa, CEO
Assessment: Measured rollout. Revenue contribution materially in 2027+.
ASC Strategy Multi-Year
Q: "ASC strategy through XiR — what's the contribution outlook?"
— David Roman, Goldman Sachs
A: "Our initiative currently leverages our XiR system and its associated ecosystem with economic and capital acquisition offerings we believe are well suited to meet the clinical and financial needs of this environment... Approximately 70% of the ASC procedure opportunity is in ASCs affiliated with our existing IDN customers."
— Jamie Samath, CFO
Assessment: ASC is multi-year strategy. IDN affiliation provides leverage.
$70M Intuitive Foundation Donation Sustainability
Q: "The $70M donation pulled forward — is this an annual cadence or true one-time pull-forward?"
— Travis Steed, BofA
A: "The increased donation to the Intuitive Foundation as compared to the $45 million donated in quarter 4 of last year reflects our decision to make a multiyear donation given the impact of new U.S. tax rules effective in 2026."
— Jamie Samath, CFO
Assessment: True multi-year pull-forward. 2026 should have lower donation impact.
Q4 Buyback Slow Pace
Q: "Q4 buyback only $201M vs Q3's $1.9B. Why the moderation?"
— Anthony Petrone, Mizuho
A: "We ended the year with $9 billion in cash and investments, up from $8.4 billion last quarter driven primarily by cash from operations, partially offset by stock repurchases of $201 million and capital expenditures of $155 million."
— Jamie Samath, CFO
Assessment: Buyback pace modulated by stock price recovery. Opportunistic posture preserved.
What They're NOT Saying
- Specific FY26 EPS guidance (none provided)
- Cardiac dV5 procedure forecast
- SP NSM ramp timing
- ASC contribution sizing
- ACA impact quantification scenarios
- OUS dV5 placement target FY26 exit
Market Reaction
- Pre-print: Stock ~$555; YTD 2026 +1%; trailing 12M +18%; ~52x FY26 EPS
- After-hours: Flat to +1% — pre-announcement compressed surprise factor
- Jan 23 close: ~$558, +0.5% (+$3)
Muted reaction reflects (a) pre-announcement compressed surprise + (b) 2026 procedure guide deceleration tempering enthusiasm. Sell-side targets mixed — bulls maintained $600+; bears at $480-520.
Street Perspective
Debate: Is 2026 Procedure Guide Conservative or Honest?
Bull view: Conservative pattern — FY25 initial guide 15-17% finished at 18%; same pattern likely 2026 → 15-17% actual.
Bear view: Macro headwinds (ACA/Medicaid + China + Japan) genuinely materializing; 13-15% honest baseline.
Our take: Lean bull. ISRG conservative-guide pattern is consistent. Actual likely 15-16%.
Debate: Cardiac + ASC New TAM Materiality
Bull view: Cardiac + ASC + SP NSM are 2027+ revenue drivers; meaningful TAM expansion.
Bear view: Multi-year ramp; near-term contribution immaterial.
Our take: Multi-year TAM expansion compounds. Bull case validated by FY27.
Debate: ISRG Valuation Post-Run-Up
Bull view: Multi-year compounder + multiple new TAM unlocks + accelerating buyback at depressed prices.
Bear view: 52x FY26 premium; deceleration to 13-15% supports multiple compression.
Our take: Lean bull. Multi-quarter execution + multi-year growth profile + premium structural.
Model Update Needed
| Item | Prior | New |
|---|---|---|
| FY25 Revenue (Actual) | $10.0B | $10.1B |
| FY25 EPS (Actual) | $8.85 | $9.10 |
| FY26 Revenue | $11.7B | $11.6B (slight trim on guide moderation) |
| FY26 EPS | $10.40 | $10.25 |
| FY27 Revenue | $13.5B | $13.5-13.8B |
| FY27 EPS | $12.50 | $12.60-12.80 |
Valuation: PT range maintained Base $640 / Bull $720 / Bear $500. At $558 post-print: base +15%; bull +29%; bear -10%. Up/down ~2.5:1.
Thesis Scorecard
| Thesis Point | Status |
|---|---|
| Bull #1: Durable procedure growth | Confirmed (FY25 +18%) |
| Bull #2: dV5 platform mix-up | Confirmed |
| Bull #3: OUS expansion | Confirmed |
| Bull #4: Multi-platform TAM expansion (cardiac + ASC + SP NSM) | Newly Confirmed |
| Bull #5: Free cash flow inflection | Confirmed ($2.5B) |
| Bear #1: GM compression at platform transitions | Easing |
| Bear #2: OUS macro headwinds | Confirmed (Japan/China) |
| Bear #3: 2026 procedure deceleration | Newly Surfaced |
| Bear #4: ACA/Medicaid policy uncertainty | Watch List |
Action: Maintaining Outperform. Multi-year compounder thesis intact; 2026 guide deceleration concern softened by multi-platform TAM expansion + ISRG conservative-guide pattern.